+

WO2006005459A3 - Agents diagnostiques et therapeutiques pour maladies associees a l'ectoenzyme degradant l'hormone de liberation de la thyrotropine (trhde) - Google Patents

Agents diagnostiques et therapeutiques pour maladies associees a l'ectoenzyme degradant l'hormone de liberation de la thyrotropine (trhde) Download PDF

Info

Publication number
WO2006005459A3
WO2006005459A3 PCT/EP2005/007144 EP2005007144W WO2006005459A3 WO 2006005459 A3 WO2006005459 A3 WO 2006005459A3 EP 2005007144 W EP2005007144 W EP 2005007144W WO 2006005459 A3 WO2006005459 A3 WO 2006005459A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
trhde
thyrotropin
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2005/007144
Other languages
English (en)
Other versions
WO2006005459A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2006005459A2 publication Critical patent/WO2006005459A2/fr
Publication of WO2006005459A3 publication Critical patent/WO2006005459A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne une TRHDE humaine qui est associée aux maladies suivantes : maladies cardiovasculaires, infections, maladies respiratoires, maladies dermatologiques, maladies endocriniennes, maladies métaboliques, inflammation, maladies gastro-intestinales, cancer, maladies hématologiques, maladies musculo-squelettiques, maladies neurologiques et maladies urologiques. L'invention concerne également des analyses pour l'identification de composés utiles dans le traitement ou la prévention des maladies suivantes : maladies cardiovasculaires, infections, maladies respiratoires, maladies dermatologiques, maladies endocriniennes, maladies métaboliques, inflammation, maladies gastro-intestinales, cancer, maladies hématologiques, maladies musculo-squelettiques, maladies neurologiques et maladies urologiques. L'invention concerne en outre des composés qui se lient à la TRHDE et/ou qui activent ou qui inhibent l'activité de celle-ci ainsi que des compositions pharmaceutiques comprenant lesdits composés.
PCT/EP2005/007144 2004-07-15 2005-07-02 Agents diagnostiques et therapeutiques pour maladies associees a l'ectoenzyme degradant l'hormone de liberation de la thyrotropine (trhde) WO2006005459A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04016635.7 2004-07-15
EP04016635 2004-07-15

Publications (2)

Publication Number Publication Date
WO2006005459A2 WO2006005459A2 (fr) 2006-01-19
WO2006005459A3 true WO2006005459A3 (fr) 2006-06-08

Family

ID=35432524

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/007144 WO2006005459A2 (fr) 2004-07-15 2005-07-02 Agents diagnostiques et therapeutiques pour maladies associees a l'ectoenzyme degradant l'hormone de liberation de la thyrotropine (trhde)

Country Status (1)

Country Link
WO (1) WO2006005459A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE20060253A1 (en) * 2006-03-31 2007-11-14 Trinity College Dublin Methods for modulating the levels and effects of thyrotropin-releasing hormone(trh)and trh-related peptides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092113A1 (en) * 1999-12-09 2003-05-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030166944A1 (en) * 2000-02-17 2003-09-04 The Provost, Fellows And Scholars Of The College Of Th Holy TRH-like peptide derivatives as inhibitors of the TRH-degrading ectoenzyme

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092113A1 (en) * 1999-12-09 2003-05-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030166944A1 (en) * 2000-02-17 2003-09-04 The Provost, Fellows And Scholars Of The College Of Th Holy TRH-like peptide derivatives as inhibitors of the TRH-degrading ectoenzyme

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CUMMINS P M ET AL: "Pyroglutamyl peptidase: an overview of the three known enzymatic forms", BIOCHIMICA ET BIOPHYSICA ACTA. PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, ELSEVIER, AMSTERDAM,, NL, vol. 1429, no. 1, 8 December 1998 (1998-12-08), pages 1 - 17, XP004278561, ISSN: 0167-4838 *
EHRCHEN JAN ET AL: "Analysis of thyrotropin-releasing hormone-signaling components in pituitary adenomas of patients with acromegaly", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 85, no. 8, August 2000 (2000-08-01), pages 2709 - 2713, XP002358530, ISSN: 0021-972X *

Also Published As

Publication number Publication date
WO2006005459A2 (fr) 2006-01-19

Similar Documents

Publication Publication Date Title
WO2006027147A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur d'adrenomedulline (amdr)
WO2005106012A3 (fr) Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 1 (dpp1)
WO2006010517A3 (fr) Diagnostic et traitement therapeutique des maladies associees a la proteine d'activation des fibroblastes (fap)
WO2005100990A3 (fr) Methodes diagnostiques et therapeutiques pour des maladies associees au purinocepteur 2 de type y (p2y2)
WO2006005469A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees au recepteur de glucagon (gcgr)
WO2005114207A3 (fr) Diagnostic et traitement de maladies associees a l'aminopeptidase n (anpep)
WO2005103684A3 (fr) Diagnostics et methodes therapeutiqeus pour des maladies associees au recepteur 1 de la chimiokine cx3c
WO2006005459A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees a l'ectoenzyme degradant l'hormone de liberation de la thyrotropine (trhde)
WO2006021343A3 (fr) Diagnostic et therapie de maladies associees au recepteur 3a de la 5-hydroxytryptamine (5-ht3a)
WO2005076007A3 (fr) Diagnostics et traitements de maladies associees au recepteur p2y12 couple a la proteine g (p2y12)
WO2005113786A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees a la chymase (cma1)
WO2005090994A3 (fr) Diagnostic et therapeutique pour des maladies associees a la proteine kinase, dependante de cgmp, type 1 (prkg1)
WO2006008003A3 (fr) Agents diagnostiques et therapeutiques pour pathologies associees au recepteur 1 de peptide intestinal vasoactif (vpac1)
WO2005106486A3 (fr) Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 3 (dpp3)
WO2005073729A3 (fr) Diagnostic et traitement de maladies associees au recepteur p2y11 couple a une proteine g (p2y11)
WO2006013013A3 (fr) Agents pour le diagnostic et le traitement de maladies associees a la proteine protectrice pour la beta-galactosidase (ppgb)
WO2006013014A3 (fr) Diagnostics et therapeutiques pour maladies liees a une proteine similaire a un antigene membranaire specifique de la prostate (psmal)
WO2006010497A3 (fr) Diagnostics et therapeutiques pour des maladies associees a choline kinase (chk)
WO2005119263A3 (fr) Diagnostic et traitement des maladies associees au recepteur couple aux proteines g 92 (gpr92)
WO2006013012A3 (fr) Diagnostics et therapeutique pour maladies liees a la napsine 1 (nap1)
WO2006013015A3 (fr) Diagnostics et therapeutique pour maladies liees a la marapsine (mpn)
WO2005075983A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a un recepteur nucleaire humain nr4a3 (nr4a3)
WO2005114210A8 (fr) Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees a la kinase 3 specifique du recepteur couple a une proteine g (grk3)
WO2005095631A3 (fr) Diagnostics et therapies pour maladies associees a la kinase 4 alpha de lignee mixte (mlk4 alpha)
WO2006040047A3 (fr) Diagnostics et therapeutiques pour des maladies associees a la kinase citron agissant sur rho/rac

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载